Why BioAI is Needed?
Last updated
Last updated
In the traditional healthcare model, the success rate of drug development is low, new drug development cycles are long, and developing countries struggle to access innovative treatments. Patient data is often controlled by pharmaceutical companies, and patients rarely benefit from it. Here's how BioAI addresses these industry pain points through decentralization and AI technology:
What sets BioAI apart is its fusion of decentralization and intelligence. Through the collaboration of AI technology and blockchain, BioAI creates a new healthcare ecosystem with the following core features:
Decentralized Drug Development Traditional drug development often relies on large pharmaceutical companies and centralized research institutions. BioAI, however, uses a decentralized network, allowing global researchers, patients, and investors to participate in the drug development process. Users are not just data providers, but active participants in research and ultimately share the results.
Smart Contract-Driven Clinical Trials BioAI uses smart contract technology to automate the management of clinical trials, from patient recruitment and matching to data collection and analysis. This reduces intermediaries, increases trial efficiency, and ensures transparency and fairness through real-time tracking and feedback.
Data as Contribution in Medical DAO On the BioAI platform, users contribute data by uploading personal health data, participating in clinical trials, and completing research tasks. They can engage in decentralized decision-making and management, earning token rewards. This "data as contribution" model solves data monopolies and unequal profit distribution, providing tangible rewards for every contributor.
Global Synchronized Medical Collaboration BioAI breaks the geographical limitations of traditional medical research through a decentralized network and intelligent technologies, enabling global researchers, patients, and healthcare institutions to participate in a shared platform. It removes barriers for developing countries and remote areas in accessing innovative treatments.
Precision Medicine and Personalized Treatment Leveraging AI’s powerful computing capabilities, BioAI provides personalized treatment plans for each patient, reducing unnecessary treatments and side effects. By analyzing patient genomics, electronic health records, and other information, BioAI helps doctors make more accurate decisions, improving treatment outcomes.
BioAI combines AI with DeSci to revolutionize traditional medical research and drug development models. In the traditional model, the connection between patients and researchers is often weak. BioAI, through decentralization, uses blockchain technology and AI capabilities to enable people from different regions around the world to share medical data and resources.
Case Study: Rare Disease Drug Development
In the traditional model, the development of drugs for rare diseases is often neglected due to the small number of patients and limited market size. In the BioAI ecosystem, any rare disease patient can upload their genetic data to the blockchain. Through AI algorithms, their data can be matched with similar cases globally, triggering drug development proposals. Once the community votes to approve, AI automatically breaks down the research tasks and assigns them. These tasks include:
Computational Chemists: Design drug structures using the simulation tools provided by the platform and receive token rewards.
Family Members of Patients: Participate in efficacy tracking, helping the platform gather real-time feedback from patients and receive daily token rewards.
Investment Institutions: Stake tokens to fund clinical trials and receive returns based on efficacy results.
Through this decentralized approach, BioAI significantly improves the efficiency of drug development, reduces research costs, provides more treatment options for patients worldwide, and allows global researchers and patients to collaboratively participate in medical innovation.
